These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates. López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715 [TBL] [Abstract][Full Text] [Related]
23. Analysis of beta-lactamases produced by cephalothin-susceptible Escherichia coli clinical isolates resistant to co-amoxiclav and ticarcillin-clavulanic acid. The CERIB Study Group. Chardon H; Farzaneh S; Labia R; Jarlier V; Nicolas MH; Paul G; Poyart C; Sirot D; Sirot J J Antimicrob Chemother; 1995 Jul; 36(1):267-9. PubMed ID: 8537279 [No Abstract] [Full Text] [Related]
24. Effect of hyperproduction of TEM-1 beta-lactamase on in vitro susceptibility of Escherichia coli to beta-lactam antibiotics. Wu PJ; Shannon K; Phillips I Antimicrob Agents Chemother; 1994 Mar; 38(3):494-8. PubMed ID: 8203843 [TBL] [Abstract][Full Text] [Related]
25. Characterization of a new TEM-type beta-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli. Blazquez J; Baquero MR; Canton R; Alos I; Baquero F Antimicrob Agents Chemother; 1993 Oct; 37(10):2059-63. PubMed ID: 8257123 [TBL] [Abstract][Full Text] [Related]
26. Efficacy of amoxycillin-clavulanate in an experimental model of murine pneumonia caused by AmpC-non-hyperproducing clinical isolates of Escherichia coli resistant to cefoxitin. Docobo-Pérez F; Fernández-Cuenca F; Pachón-Ibáñez ME; Pascual A; Pichardo C; Martínez-Martínez L; Pachón J Clin Microbiol Infect; 2008 Jun; 14(6):582-7. PubMed ID: 18294246 [TBL] [Abstract][Full Text] [Related]
27. Plasmid encoded beta-lactamases resistant to inhibition by clavulanic acid produced by calf faecal coliforms. Hunter JE; Corkill JE; McLennan AG; Fletcher JN; Hart CA Res Vet Sci; 1993 Nov; 55(3):367-70. PubMed ID: 8284502 [TBL] [Abstract][Full Text] [Related]
28. In vitro activity of mecillinam and amoxicillin/clavulanic acid against strains of Escherichia coli producing TEM-1, Oxa-1 and chromosomal beta-lactamases. Marre R; Schulz E Arzneimittelforschung; 1988 Jul; 38(7):863-5. PubMed ID: 3061383 [TBL] [Abstract][Full Text] [Related]
29. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Rodríguez-Baño J; Alcalá JC; Cisneros JM; Grill F; Oliver A; Horcajada JP; Tórtola T; Mirelis B; Navarro G; Cuenca M; Esteve M; Peña C; Llanos AC; Cantón R; Pascual A Arch Intern Med; 2008 Sep; 168(17):1897-902. PubMed ID: 18809817 [TBL] [Abstract][Full Text] [Related]
30. beta-Lactam resistance phenotype determination in Escherichia coli isolates from University Malaya Medical Centre. Wong JS; Mohd Azri ZA; Subramaniam G; Ho SE; Palasubramaniam S; Navaratnam P Malays J Pathol; 2003 Dec; 25(2):113-9. PubMed ID: 16196367 [TBL] [Abstract][Full Text] [Related]
31. Back mutations to the TEM-1 beta-lactamase from TRC-1 lead to restored sensitivity to clavulanic acid. Thomson CJ; Amyes SG J Med Microbiol; 1995 Jun; 42(6):429-32. PubMed ID: 7791208 [TBL] [Abstract][Full Text] [Related]
32. Amoxycillin/clavulanate resistant Escherichia coli. Williams H; King A; Shannon K; Phillips I Lancet; 1988 Feb; 1(8580):304-5. PubMed ID: 2893121 [No Abstract] [Full Text] [Related]
33. Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Lampri N; Galani I; Poulakou G; Katsarolis I; Petrikkos G; Giamarellou H; Souli M J Antimicrob Chemother; 2012 Oct; 67(10):2424-8. PubMed ID: 22665388 [TBL] [Abstract][Full Text] [Related]
34. Beta-lactamase evaluation of the amoxycillin-clavulanate association. Novelli A; Reali EF; Fallani S; Periti P Drugs Exp Clin Res; 1989; 15(4):151-4. PubMed ID: 2505995 [TBL] [Abstract][Full Text] [Related]
35. Emergence of clinical isolates of Escherichia coli producing TEM-1 derivatives or an OXA-1 beta-lactamase conferring resistance to beta-lactamase inhibitors. Zhou XY; Bordon F; Sirot D; Kitzis MD; Gutmann L Antimicrob Agents Chemother; 1994 May; 38(5):1085-9. PubMed ID: 8067742 [TBL] [Abstract][Full Text] [Related]
36. Susceptibility of Escherichia coli to the amoxycillin-clavulanate combination: which recommendations should be used to provide relevant information to clinicians? Patry I; Hocquet D; Talon D; Plesiat P; Bertrand X Clin Microbiol Infect; 2005 Mar; 11(3):237-40. PubMed ID: 15715724 [TBL] [Abstract][Full Text] [Related]
37. Selection of variants of the TEM-1 beta-lactamase, encoded by a plasmid of clinical origin, with increased resistance to beta-lactamase inhibitors. Thomson CJ; Amyes SG J Antimicrob Chemother; 1993 May; 31(5):655-64. PubMed ID: 8392995 [TBL] [Abstract][Full Text] [Related]
38. [Urinary tract infections in children. Status in a pediatric hospital and sensitivity of bacterial strains to amoxycillin-clavulanic acid combination]. Cochat N; Barbe G; Boutin-Tranchant ME; Cochat P Pediatrie; 1987; 42(4):309-14. PubMed ID: 3671031 [TBL] [Abstract][Full Text] [Related]
39. Effect of low concentrations of clavulanic acid on the in-vitro activity of amoxycillin against beta-lactamase-producing Branhamella catarrhalis and Haemophilus influenzae. Cooper CE; Slocombe B; White AR J Antimicrob Chemother; 1990 Sep; 26(3):371-80. PubMed ID: 2121699 [TBL] [Abstract][Full Text] [Related]
40. Nucleotide sequences of the genes coding for the TEM-like beta-lactamases IRT-1 and IRT-2 (formerly called TRI-1 and TRI-2). Belaaouaj A; Lapoumeroulie C; Caniça MM; Vedel G; Névot P; Krishnamoorthy R; Paul G FEMS Microbiol Lett; 1994 Jul; 120(1-2):75-80. PubMed ID: 8056297 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]